12 research outputs found
The European âClinical Trialâ Regulation; Relationship with the JardĂ© Act: a Giens Workshop
In May 2014, the European Union Parliament and Council published a new regulation on
clinical trials on medicinal products for human use, which is designed to replace
Directive 2001/20/EC. It will not come into effect until 2016. Nevertheless, it is
essential to examine its relationship with national legislation, i.e. the Jardé Act, whose
implementation has been delayed pending publication of the European regulation. The Giens
workshop identified and examined the various issues that this relationship is bound to
raise. In particular, it looked at trial methodology assessment procedures, the working
relationship between the French National Agency of Drug Safety and Health Products
(Agence Nationale de Sécurité du Médicament et des Produits de Santé,
ANSM) and ethics committees during the authorization application evaluation phase, review
of post-authorization/registration studies on medicinal products and medical devices, and
data transparency.
Abbreviations: see end of article
Le rÚglement européen «essais cliniques» : articulation avec la loi Jardé : un atelier de Giens
Le Parlement et le Conseil de lâUnion EuropĂ©enne ont publiĂ© en mai 2014 un nouveau
rÚglement relatif aux essais cliniques de médicaments, destiné à remplacer la directive
2001/20/CE. Sa mise en application nâinterviendra pas avant 2016. NĂ©anmoins, il est
essentiel de se prĂ©occuper dĂšs Ă prĂ©sent de lâarticulation de ce texte avec la lĂ©gislation
nationale, câest-Ă -dire de la loi JardĂ© dont la mise en Ćuvre a Ă©tĂ© retardĂ©e, prĂ©cisĂ©ment
dans lâattente de la publication du rĂšglement europĂ©en. Lâatelier de Giens a listĂ© et
étudié les différents problÚmes que cette articulation ne manquera pas de poser. Ont été
particuliĂšrement abordĂ©s : les modalitĂ©s dâĂ©valuation de la mĂ©thodologie des essais,
lâarticulation fonctionnelle entre lâAgence Nationale de SĂ©curitĂ© du MĂ©dicament et des
Produits de Santé (ANSM) et les Comités de Protection des Personnes (CPP) pendant cette
phase dâĂ©valuation des demandes dâautorisation, lâĂ©valuation des Ă©tudes
post-autorisation/inscription des médicaments et des dispositions médicaux, la
transparence des données.
AbrĂ©viations : voir en fin dâarticle
The European âClinical Trialâ Regulation: Relationship with the JardĂ© Act: a Giens Workshop
In May 2014, the European Union Parliament and Council published a new regulation on
clinical trials on medicinal products for human use, which is designed to replace
Directive 2001/20/EC. It will not come into effect until 2016. Nevertheless, it is
essential to examine its relationship with national legislation, i.e. the Jardé Act, whose
implementation has been delayed pending publication of the European regulation. The Giens
workshop identified and examined the various issues that this relationship is bound to
raise. In particular, it looked at trial methodology assessment procedures, the working
relationship between the French National Agency of Drug Safety and Health Products
(Agence Nationale de Sécurité du Médicament et des Produits de Santé,
ANSM) and ethics committees during the authorization application evaluation phase, review
of post-authorization/registration studies on medicinal products and medical devices, and
data transparency.
Abbreviations: see end of article
[Swallowing disorders, pneumonia and respiratory tract infectious disease in the elderly] : Troubles de la déglutition du sujet ùgé et pneumopathies en 14 questions/réponses
International audienceSwallowing disorders (or dysphagia) are common in the elderly and their prevalence is often underestimated. They may result in serious complications including dehydration, malnutrition, airway obstruction, aspiration pneumonia (infectious process) or pneumonitis (chemical injury caused by the inhalation of sterile gastric contents). Moreover the repercussions of dysphagia are not only physical but also emotional and social, leading to depression, altered quality of life, and social isolation. While some changes in swallowing may be a natural result of aging, dysphagia in the elderly is mainly due to central nervous system diseases such as stroke, parkinsonism, dementia, medications, local oral and oesophageal factors. To be effective, management requires a multidisciplinary team approach and a careful assessment of the patient's oropharyngeal anatomy and physiology, medical and nutritional status, cognition, language and behaviour. Clinical evaluation can be completed by a videofluoroscopic study which enables observation of bolus movement and movements of the oral cavity, pharynx and larynx throughout the swallow. The treatment depends on the underlying cause, extent of dysphagia and prognosis. Various categories of treatment are available, including compensatory strategies (postural changes and dietary modification), direct or indirect therapy techniques (swallow manoeuvres, medication and surgical procedures)